People with heart failure, diabetes and/or hypertension Other
Conditions
Interventions
The researchers will study people with and without diabetes, and people with and without heart failure. Following informed consent, all participants will have a baseline assessment (this may be done a
Sponsors
University of Dundee
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All individuals must be aged =18 years. Seven groups of participants will be included: Group 1 participants: Documented diagnosis of Type 1 diabetes (T1D) and heart failure (HF). Diagnosis of HF, regardless of left ventricular ejection fraction (LVEF), will be defined as one or more of the following: 1. Previous HF hospitalisation where HF was documented as the primary cause of hospitalisation and there was a requirement for loop diuretics. 2. Impaired left ventricular (LV) function (i.e. LVEF 29 ml/m2) 3.2. Preserved LV systolic function (LVEF =50%) with left ventricular hypertrophy (2-dimensional echocardiographic measurement of end-diastolic interventricular septal diameter =1.2cm or end-diastolic left ventricular posterior wall diameter =1.2 cm). 3.3. Preserved LV systolic function (LVEF =50%) with echocardiographic diastolic dysfunction (septal e’ <7 cm/sec or lateral e’ <10 cm/sec or average E/e’ =15). Group 2 participants: Documented diagnosis of Type 2 diabetes (T2D) and heart failure (HF) as defined for group 1. Group 3 participants: Diagnosis of HF as defined for group 1 without diabetes (type 1 or type 2). Group 4 participants: Diagnosis of Type 1 diabetes without heart failure. Group 5 participants: Diagnosis of Type 2 diabetes without heart failure. Group 6 participants: Documented diagnosis of hypertension on at least 2 anti-hypertensive drugs, without a diagnosis of heart failure or diabetes. Group 7 participants: Individuals with no prior diagnosis of cardiovascular disease, diabetes or hypertension.
Exclusion criteria
Exclusion criteria: 1. End-stage heart failure requiring left ventricular assist devices, intra-aortic balloon pump, or any type of mechanical support at the time of recruitment 2. Documented primary severe valvular heart disease, amyloidosis or hypertrophic cardiomyopathy as the principal cause of heart failure as judged by the investigator 3. Presence of malignancy with expected life expectancy <1 year at screening 4. Contraindications to MRI, including claustrophobia, metal implants in the body deemed not MRI safe 5. Severe asthma requiring admission to intensive care in the last 2 years 6. Unable/unwilling to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Stress myocardial blood flow measured in ml/g/min during adenosine stress cardiovascular magnetic resonance (CMR) at baseline and 2 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Myocardial perfusion reserve (units) during adenosine stress CMR at baseline and 2 years. 2. Incidence of new heart failure diagnosis (percentage) at 2 years | — |
Countries
Scotland, United Kingdom
Contacts
Public ContactIfy Mordi
Outcome results
None listed